CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 433 enrolled
Drug / intervention
Cervarix +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00518336
NCT00518336Phase 2Completed

Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

GlaxoSmithKline·interventional·Posted Aug 20, 2007·Updated Dec 9, 2016

In Brief

A Phase 2 clinical trial evaluating Blood sampling, Collection of cervical specimen, and 1 other intervention for Infections, Papillomavirus. Completed, enrolled 433 participants across 5 sites.

Detailed Summary

Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IIb study is designed to evaluate the the long-term efficacy, safety and immunogenicity of the 580299 HPV vaccine (CervarixTM) in a Brazilian cohort of women vaccinated in the phase IIb, blinded, primary study 580299/001 (NCT00689741) and having participated in follow-up study 580299/007 (NCT00120848). Only subjects who participated in the primary \& follow-up study will be enrolled in this long-term follow-up study. Subjects were aged 15-25 years at the time of entry into the primary study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 20, 2007
Enrollment StartNov 1, 2007
Primary CompletionJul 1, 2008
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.9 years ago

Interventions

Blood samplingprocedure

Blood sampling at Visit 3, 5 and 7.

Collection of cervical specimenprocedure

Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.

Cervarixbiological

Three doses administered intramuscularly at 0, 1 and 6 months.